Lv1
30 积分 2024-10-25 加入
An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes
12小时前
待确认
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations
6天前
已完结
MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC
10天前
已完结
Inhibitors and PROTACs of CDK2: challenges and opportunities
22天前
已完结
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations
22天前
已完结
Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
1个月前
已关闭
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
1个月前
已完结
A ROS-dependent mechanism promotes CDK2 phosphorylation to drive progression through S phase
1个月前
已完结
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2个月前
已完结
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
2个月前
已完结
皖公网安备34019202002308
